RGEN: Repligen Inc. Growth-Adjusted Market Cap to Net Income
The growth stock attractiveness indicator allows for a valuation of Repligen Corporation (RGEN) based on competent management and precise M&A. The business relies on the sterile transport of reagents and the implementation of automated filtration systems. This chart helps identify the asset's undervaluation, while 2.53 represents the latest metric reading, signaling the company's fundamental potential within the bioprocessing sector.
Repligen Corporation (RGEN) - metric breakdowns and financial figures
- current price and projected stock value:
- market capitalization information:
- company book value details:
- debt obligations and liquidity statistics:
- earnings and market multiples details:
RGEN - Company Net Income|Forward Earnings Repligen Corporation|RGEN - Price to Earnings Ratio|Projected Price to Earnings Ratio Repligen Inc.|RGEN - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Repligen Corp.|RGEN - Operating profit EBITDA|Net earnings per share (EPS TTM) Repligen|RGEN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months repligen.com|RGEN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Repligen Corporation
General company analysis:RGEN (Repligen Corp)
The PEG ratio measures investment efficiency by comparing the current P/E multiple to earnings expansion rates, enabling the identification of undervalued assets with high growth potential. Analyzing the ratio of P/E to expected EPS growth separates market noise from fundamental value, confirming the premium status of Repligen Corporation (RGEN) due to its exceptional pricing power in the biopharmaceutical filtration niche.
Competitors of Repligen Corporation
Price/Earnings to Growth Ratio TEM (Tempus AI, Inc)|PEG Multiple QGEN (Qiagen Group)|Growth-Adjusted Market Cap to Net Income Isis Pharmaceuticals (IONS)|Avidity Biosciences - PEG Multiple|Price to Net Income Growth Ratio crisprtx.com (CRSP)|WGS: PEG Multiple|Price to Earnings Adjusted for Growth Rate Ultragenyx Pharmaceutical Inc. (RARE)|Price/Earnings to Growth Ratio Beam Therapeutics Corp|Growth-Adjusted P/E Ratio SRPT (Sarepta Corp)|Price/Earnings to Growth Multiple TWST (Twist Bioscience)|TXG (10xgenomics.com) - Growth-Adjusted Payback Ratio|PEG Multiple NTLA (Intellia Therapeutics, Inc.)|STOK - Price/Earnings to Growth Multiple|BLFS - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Wave Pharma|Maze Therapeutics Inc (MAZE) - Price/Earnings to Growth Ratio|sionnatx.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Prime Medicine|Taysha Gene Therapies Inc - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio uniQure Corp (QURE)|MGTX - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio REGENXBIO Inc. RGNX|Growth-Adjusted Payback Ratio SLDB|Ocugen - PEG Multiple|PACB - PEG Multiple|BNTC (Benitec) - Price/Earnings to Growth Multiple|DSGN: Company Value to Earnings Growth Ratio|RCKT (Rocket Pharmaceuticals) - PEG Multiple|4dmoleculartherapeutics.com (FDMT) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Lexeo Therapeutics (LXEO)|KRRO - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Editas EDIT|SLN: Growth-Adjusted P/E Ratio|PRQR - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio CDXS (Codexis, Inc.)|SGMO: PEG Multiple|Price to Net Income Growth Ratio Nautilus Bio NAUT|MGX (Metagenomi, Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Precision BioSciences Inc. DTIL|Price/Earnings to Growth Ratio Generation Bio Co. (GBIO)|boundlessbio.com - Growth-Adjusted P/E Ratio|PEG Multiple XCUR (Exicure)|IMNN: Growth-Adjusted P/E Ratio|PHIO - Price/Earnings to Growth Ratio|MBIO (Mustang Bio, Inc.) - Growth-Adjusted P/E Ratio|RNAZ: PEG Multiple|Bionano Genomics (BNGO) - PEG Multiple|Price/Earnings to Growth Ratio Applied DNA Sciences, Inc.|BLUE: Growth-Adjusted Payback Ratio|PEG Multiple IPA|OMGA - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Singular Genomics Systems OMIC|RGLS (regulusrx.com) - Market Cap to Earnings and Growth Ratio|SYRS - Price/Earnings to Growth Ratio|TBIO: Price/Earnings to Growth Ratio|TCON: PEG Multiple|UBX - Growth-Adjusted Market Cap to Net Income
